Biogen Inc (BUE:BIIB)
ARS 18636 201.5 (1.09%) Market Cap: 28.98 Til Enterprise Value: 34.17 Til PE Ratio: 28.13 PB Ratio: 2.14 GF Score: 49/100

Biogen Inc at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 11:30PM GMT
Cory William Kasimov
JP Morgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good afternoon, everyone. My name is Cory Kasimov. I'm the senior large cap biotech analyst at JPMorgan, and it's my pleasure to introduce our next company, Biogen. Obviously, looking at a very important 2020 and here to tell us about it is the company's CEO, Michel Vounatsos. And please note that following Michel's presentation is a breakout just down the hall in the [Georgian] room.

With that, I'll turn it over to Michel.

Michel Vounatsos
Biogen Inc. - CEO & Director

Thank you so much. Good afternoon, everyone. I hope you're doing well. It's a pleasure being here and having the opportunity to give you an update on our progress at Biogen on the way to build a multifranchise portfolio focusing on neuroscience and the huge opportunity it offers.

I fundamentally believe that Biogen is facing a clear inflection points with many near-term opportunities obviously in the field of Alzheimer's disease with a decision to go to file, but

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot